BartalenaL, FatourechiV. 2014. Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest, 37:691–700.
2.
TandaML, PiantanidaE, LiparuloL, VeronesiG, LaiA, SassiL, ParianiN, GalloD, AzzoliniC, FerrarioM, BartalenaL. 2013. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab, 98:1443–1449.
3.
PiantanidaE, TandaML, LaiA, SassiL, BartalenaL. 2013. Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest, 36:444–449.
4.
TraiskF, TallstedtL, Abraham-NordlingM, AnderssonT, BergG, CalissendorfJ, HallengrenB, HednerP, lantzM, NystromE, PnjavicV, TaubeA, TorringO, WallinG, AsmanP, LundellG. 2009. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab, 94:3700–3707.
5.
TallstedtL, LundellG, BlomgrenH, BringJ. 1994. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?. Eur J Endocrinol, 130:494–497.
6.
BartalenaL. 2011. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab, 96:592–599.
7.
ShiberS, Stiebel-KalishH, ShimonI, GrossmanA, RobensthokE. 2014. Glucocorticoids regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment—Systematic review and meta-analysis. Thyroid, 24:1515–1523.
8.
BartalenaL, KrassasGE, WiersingaW, MarcocciC, SalviM, DaumerieC, BournaudC, StahlM, SassiL, VeronesiC, AzzoliniC, BoboridisKG, MouritsMP, SoetersMR, BaldeschiL, NardiM, CurròN, BoschiA, BernardM, von ArxG, European Group on Graves'Orbitopathy. 2012. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab, 97:4454–4463.
9.
PerrosP, Kendall-TaylorP, NeohC, FrewinS, DickinsonJ. 2005. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab, 90:5321–5323.
